BioSpace News Archive

In an eight-week study, Biostrap Labs, the research division of the progressive digital health company Biostrap, found that short-term effects of the BioLight low-level light therapy (LLLT) reduced physiological stress, perceived musculoskeletal pain and muscle soreness of participants indicating long-term effects on health and performance.

In alignment with its strategic plan for growth and readiness for going public, biolog-id, a global leader in the traceability of sensitive therapeutic products, reinforces its executive team by appointing Eric Dutang as Chief Financial Officer and Deputy CEO.

GT Molecular, a company providing multiplexed, ultrasensitive PCR assays for wastewater-based epidemiology, cancer and pathogen panels, has announced the upcoming release of its sensitive PCR tests to monitor the coronavirus Omicron variant, B.1.1.529.

Epic Sciences, Inc. (Epic)'s comprehensive liquid-biopsy platform continues to deliver compelling cancer profiling information as data presented during the San Antonio Breast Cancer Symposium 2021 demonstrate.

Growing prevalence of cancer, cardiovascular diseases, musculoskeletal disorders, neurological diseases, and autoimmune disorders, and rapid adoption of regenerative medicine are among the key factors expected to drive market revenue growth.

Technological advancements in insulin delivery devices, rapid development of advanced healthcare infrastructure, and rising awareness of diabetes treatment are some key factors expected to drive market growth.

Increasing incidence of diabetic population, launch of advanced wearable blood glucose meters, and rising government initiatives for availability of advanced healthcare facilities are some key factors expected to drive market growth.

According to Emergen Research, the global nutrigenomics market size was USD 389.4 Million in 2020 and is expected to reach USD 1,289.7 Million in 2028 and register a revenue CAGR of 16.2% during the forecast period, 2021-2028.

Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced that the National Medical Products Administration (NMPA) of China has granted approval of the company’s monoclonal neutralizing antibody (mAb) therapy.

The global whole exome sequencing market revenue growth has gained momentum over the recent past due to many favorable factors.